Strs Ohio Voyager Therapeutics, Inc. Transaction History

Strs Ohio

$25.5 Billion
Q3 2024

A detailed history of Strs Ohio transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Strs Ohio holds 69,800 shares of VYGR stock, worth $434,156. This represents 0.0% of its overall portfolio holdings.

Number of Shares

69,800

Previous 61,100 14.24%

Holding current value

$434,156

Previous $483,000 15.53%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$5.77 - $9.27 $50,198 - $80,649	8,700 Added 14.24%	69,800 $408,000
Q2 2024 Aug 05, 2024	BUY	$7.42 - $10.54 $207,760 - $295,120	28,000 Added 84.59%	61,100 $483,000
Q1 2024 May 13, 2024	BUY	$7.15 - $10.84 $103,675 - $157,180	14,500 Added 77.96%	33,100 $308,000
Q3 2023 Oct 26, 2023	SELL	$7.55 - $11.25 $80,785 - $120,375	-10,700 Reduced 36.52%	18,600 $144,000
Q2 2023 Jul 31, 2023	BUY	$6.94 - $13.99 $203,342 - $409,907	29,300 New	29,300 $335,000
Q2 2021 Jul 26, 2021	SELL	$3.94 - $5.44 $524,808 - $724,608	-133,200 Closed	0 $0
Q1 2021 Apr 23, 2021	BUY	$4.61 - $9.04 $257,699 - $505,335	55,900 Added 72.32%	133,200 $627,000
Q4 2020 Jan 25, 2021	BUY	$7.15 - $12.28 $275,990 - $474,008	38,600 Added 99.74%	77,300 $552,000
Q2 2020 Jul 23, 2020	SELL	$8.05 - $14.21 $53,935 - $95,207	-6,700 Reduced 14.76%	38,700 $488,000
Q4 2019 Jan 24, 2020	BUY	$12.82 - $16.85 $121,790 - $160,075	9,500 Added 26.46%	45,400 $633,000
Q3 2019 Oct 21, 2019	BUY	$16.31 - $28.29 $241,387 - $418,692	14,800 Added 70.14%	35,900 $617,000
Q2 2019 Jul 25, 2019	BUY	$19.18 - $27.88 $404,698 - $588,268	21,100 New	21,100 $574,000

Others Institutions Holding VYGR

# of Institutions

130

Shares Held

34.7M

Call Options Held

39.7K

Put Options Held

34.6K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $240M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account